Find Y27632 manufacturers, exporters & distributors on PharmaCompass

Y27632

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

5DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 146986-50-7, Y-27632, Y27632, Y 27632, Cyclohexanecarboxamide, 4-[(1r)-1-aminoethyl]-n-4-pyridinyl-, trans-, 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide

Molecular Formula

C₁₄H₂₁N₃O

Molecular Weight

247.34 g/mol

InChI Key

IYOZTVGMEWJPKR-VOMCLLRMSA-N

FDA UNII

0X370ROP6H

Y-27632 is an inhibitor of Rho-associated protein kinase. It inhibits calcium sensitization to affect smooth muscle relaxation.

1 2D Structure

Y27632

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide

2.1.2 InChI

InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11?,12?/m1/s1

2.1.3 InChI Key

IYOZTVGMEWJPKR-VOMCLLRMSA-N

2.1.4 Canonical SMILES

CC(C1CCC(CC1)C(=O)NC2=CC=NC=C2)N

2.1.5 Isomeric SMILES

C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N

2.2 Other Identifiers

2.2.1 UNII

0X370ROP6H

2.3 Synonyms

2.3.1 MeSH Synonyms

1. N-(4-pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide

2. Y 27632

3. Y 27632, (4(r)-trans)-isomer

4. Y 27632, (4(s)-trans)-isomer

5. Y 27632, (trans)-isomer

6. Y 27632, Dihydrochloride, (4(r)-trans)-isomer

7. Y-27632

8. Y27632

2.3.2 Depositor-Supplied Synonyms

1. 146986-50-7

2. Y-27632

3. Y27632

4. Y 27632

5. Cyclohexanecarboxamide, 4-[(1r)-1-aminoethyl]-n-4-pyridinyl-, Trans-

6. 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide

7. Y-27632, Free Base

8. 4-[(1r)-1-aminoethyl]-n-(pyridin-4-yl)cyclohexane-1-carboxamide

9. 0x370rop6h

10. Chebi:75393

11. (r)-trans-4-(1-aminoethyl)-n-(4-pyridyl) Cyclohexanecarboxamide

12. 521059-79-0

13. (1r,4r)-4-((r)-1-aminoethyl)-n-(pyridin-4-yl)cyclohexanecarboxamide

14. (r)-(+)-trans-n-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide

15. Ximelegatran

16. (r)-4-(1-aminoethyl)-n-(pyridin-4-yl)cyclohexanecarboxamide

17. Trans-4-((r)-1-aminoethyl)-n-(pyridin-4-yl)cyclohexanecarboxamide

18. Y27

19. Unii-0x370rop6h

20. (+)-(r)-trans-4-(1-aminoethyl)-n-(4-pyridyl)cyclohexanecarboxamide

21. [+]-[r]-trans-4-[1-aminoethyl]-n-[4-pyridyl]cyclohexanecarboxamide

22. Cyclohexanecarboxamide, 4-(1-aminoethyl)-n-4-pyridinyl-, [4(r)-trans]-

23. 2etr

24. 2gnf

25. 2gnj

26. Cyclohexanecarboxamide, 4-((1r)-1-aminoethyl)-n-4-pyridinyl-, Trans-

27. Cyclohexanecarboxamide, 4-(1-aminoethyl)-n-4-pyridinyl-, (4(r)-trans)-

28. Iyoztvgmewjpkr-vomcllrmsa-n

29. 1q8t

30. Biomolki_000071

31. Y27632 Dihydrochloride

32. Biomolki2_000075

33. Cbiol_001962

34. Bspbio_001234

35. Kbiogr_000574

36. Kbioss_000574

37. Schembl598993

38. Chembl559147

39. Gtpl5290

40. Rock Inhibitor, Y-27632

41. Schembl1980406

42. Schembl7804373

43. Chembl1083134

44. Chembl1188380

45. Dtxsid7043740

46. Schembl13970844

47. Schembl18935698

48. Y-27632dihydrochloride

49. Bdbm14029

50. Bdbm86729

51. Chebi:92773

52. Kbio2_000574

53. Kbio2_003142

54. Kbio2_005710

55. Kbio3_001027

56. Kbio3_001028

57. 4-[(1r)-1-aminoethyl]-n-(4-pyridyl)cyclohexanecarboxamide

58. Bcpp000008

59. Bio1_000248

60. Bio1_000737

61. Bio1_001226

62. Bio2_000457

63. Bio2_000937

64. Hms1362n15

65. Hms1792n15

66. Hms1990n15

67. Hms3403n15

68. Y 27632 [who-dd]

69. Bdbm50319631

70. Nsc751297

71. S6390

72. (1r,4r)-4-[(1r)-1-aminoethyl]-n-(pyridin-4-yl)cyclohexane-1-carboxamide

73. Akos026750241

74. Akos028109253

75. Am81233

76. Ccg-204428

77. Cs-0131

78. Db08756

79. Nsc-751297

80. Idi1_002212

81. Smp2_000199

82. Ncgc00092276-02

83. Ncgc00092276-03

84. Ncgc00092276-04

85. Ncgc00092276-05

86. Ncgc00092276-06

87. Ncgc00092276-07

88. Ncgc00092276-08

89. Ncgc00092276-09

90. Ncgc00092276-10

91. Ncgc00387412-04

92. As-77772

93. Hy-10071

94. J888.082d

95. Cas_146986-50-7

96. Ns00073644

97. A25646

98. J-008296

99. J-525164

100. Q6584634

101. Brd-k44084986-001-03-9

102. Brd-k44084986-300-02-7

103. (r)-trans-4-(1-aminoethyl)-n-(4-pyridyl)cyclohexanecarboxamide

104. Trans-4-[(1r)-1-aminoethyl]-n-(pyridin-4-yl)cyclohexanecarboxamide

105. Trans-4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexanecarboxamide

106. (1r,4r)-4-((r)-1-aminoethyl)-n-(pyridin-4-yl)cyclohexane-1-carboxamide

107. (r)-(+)-trans-4-(1-aminoethyl)-n-(4-pyridyl)cyclohexanecarboxamide

108. 4.beta.-((1r)-1-aminoethyl)-n-(4-pyridinyl)cyclohexane-1.alpha.-carboxamide

109. Cyclohexanecarboxamide, 4-[(1r)-1-aminoethyl]-n-4-pyridinyl-, Trans- (9ci)

110. Trans-4-[(1r)-1-aminoethyl]-n-4-pyridinylcyclohexanecar Boxamide Dihydrochloride

2.4 Create Date

2005-06-08

3 Chemical and Physical Properties

Molecular Formula	C₁₄H₂₁N₃O
Molecular Weight	247.34 g/mol
XLogP3	0.9
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	3
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	68
Heavy Atom Count	18
Formal Charge	0
Complexity	268
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

Muscle Relaxants, Central

A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

Drugs in Development